Larson Financial Group LLC Evelo Biosciences, Inc. Transaction History

Larson Financial Group LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 05, 2022	SELL	$2.66 - $6.63 $13,672 - $34,078	-5,140 Reduced 87.43%	739 $3,000
Q4 2021 Feb 03, 2022	SELL	$6.07 - $12.0 $144,623 - $285,912	-23,826 Reduced 80.21%	5,879 $36,000
Q3 2021 Nov 04, 2021	SELL	$6.79 - $13.9 $11,196 - $22,921	-1,649 Reduced 5.26%	29,705 $209,000
Q2 2021 Aug 10, 2021	BUY	$9.43 - $16.6 $1,027 - $1,809	109 Added 0.35%	31,354 $431,000
Q1 2021 May 06, 2021	BUY	$9.71 - $18.6 $28,081 - $53,791	2,892 Added 10.2%	31,245 $334,000
Q4 2020 Jan 14, 2021	BUY	$3.91 - $12.28 $23,072 - $72,464	5,901 Added 26.28%	28,353 $343,000
Q3 2020 Oct 08, 2020	BUY	$3.81 - $5.73 $9,224 - $13,872	2,421 Added 12.09%	22,452 $118,000
Q2 2020 Jul 10, 2020	SELL	$3.53 - $6.12 $38 - $67	-11 Reduced 0.05%	20,031 $98,000
Q1 2020 Apr 09, 2020	BUY	$3.21 - $7.06 $41,004 - $90,184	12,774 Added 175.76%	20,042 $75,000
Q1 2019 Apr 05, 2019	BUY	$7.5 - $15.31 $12,412 - $25,338	1,655 Added 29.49%	7,268 $58,000
Q4 2018 Feb 07, 2019	BUY	$7.29 - $13.01 $40,918 - $73,025	5,613 New	5,613 $73,000

Ticker EVLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,994,000
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...

Get notified when there are updates to the investment portfolio of Larson Financial Group LLC, based on Form 13F filings with the SEC.

Stay updated on Larson Financial Group LLC with notifications on news.